Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.

Essa Pharma is facing a call to wind down operations. Soleus Capital Management, one of the company’s largest shareholders, ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

For the first quarter of this year, J&J’s total sales of $21.9 billion was up 4.2% over the start of 2024, when accounting ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

CenExel is the latest CRO to change ownership hands. Boston-based private equity firm BayPine has acquired a majority stake ...

The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. | The companies said they will work together to train ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its ...